1. Scrip
  2. >>Business

Roche Primes New Push Via Cipla For Avastin, Actemra In India

 
• By Anju Ghangurde

Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the IL-6 inhibitor, tocilizumab (Actemra), in India as they seek to expand access in a competitive, predominantly out-of-pocket market.

Business Puzzle
ROCHE EXPECTS THE DEAL WITH CIPLA TO EXPAND ACCESS TO ITS PRODUCTS IN INDIA

Roche Products (India) Private Limited has teamed up with Cipla Ltd. to push its Avastin (bevacizumab) second brand and the arthritis treatment tocilizumab (Actemra) on the Indian market, as it seeks to take on competition and expand access to its therapies.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.